|
|
Volumn 107, Issue 6, 2015, Pages djv165-
|
|
FDA approves new agent for multiple myeloma
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
CARFILZOMIB;
DEXAMETHASONE;
HYDROXAMIC ACID;
INDOLE DERIVATIVE;
OLIGOPEPTIDE;
PANOBINOSTAT;
PYRAZINE DERIVATIVE;
CLINICAL TRIAL (TOPIC);
DISEASE FREE SURVIVAL;
DRUG ADMINISTRATION;
DRUG APPROVAL;
DRUG EFFECTS;
DRUG RESISTANCE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MULTIPLE MYELOMA;
TREATMENT OUTCOME;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BORONIC ACIDS;
CLINICAL TRIALS AS TOPIC;
DEXAMETHASONE;
DISEASE-FREE SURVIVAL;
DRUG ADMINISTRATION SCHEDULE;
DRUG APPROVAL;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
HYDROXAMIC ACIDS;
INDOLES;
MULTIPLE MYELOMA;
OLIGOPEPTIDES;
PYRAZINES;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84933522687
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djv165 Document Type: Note |
|
Times cited : (50)
|
|
References (0)
|